UC Davis Comprehensive Cancer Center | Strategic Alliance Partners

UC Davis Comprehensive Cancer Center is the only National Cancer Institute-designated center serving the Central Valley and inland Northern California, a region of more than 6 million people. Its specialists provide compassionate, comprehensive care for more than 100,000 adults and children every year and access to more than 200 active clinical trials at any given time. Its innovative research program engages more than 240 scientists at UC Davis who work collaboratively to advance discovery of new tools to diagnose and treat cancer. Patients have access to leading-edge care, including immunotherapy and other targeted treatments. Its Office of Community Outreach and Engagement addresses disparities in cancer outcomes across diverse populations, and the cancer center provides comprehensive education and workforce development programs for the next generation of clinicians and scientists. For more information, visit cancer.ucdavis.edu.

Latest from UC Davis Comprehensive Cancer Center

Introducing the UC Davis Lung Cancer Chat Room

January 10, 2013

Article

The UC Davis Lung Cancer Chat Room is an interactive meeting of learning and support for patients, families, friends and caregivers affected by lung cancer.

Dr. Gandara Describes Exciting Lung Cancer Research

October 24, 2012

Video

David R. Gandara, MD, University of California, Davis Comprehensive Cancer Center, provides his opinion on some of the most exciting research currently taking place for patients with NSCLC.

Tackling Questions on Genetic Testing

October 19, 2012

Article

The expansion of testing for genetic abnormalities in patients with advanced lung cancer is generating questions about which patients' tumors should be tested, how they should be tested, and whether they should be retested.

Dr. Gandara on Patient Selection for Molecular Testing

September 12, 2012

Video

Dr. David Gandara from the UC Davis Comprehensive Cancer Center on Patient Selection for Molecular Testing in Lung Cancer

Dr. Gandara Discusses Molecular Testing for NSCLC

August 09, 2012

Video

Dr. David Gandara, from University of California, Davis Comprehensive Cancer Center, discusses using the multiplexing assay for patients with non-small cell lung cancer

TS Expression Explored in ALK-positive NSCLC

August 01, 2012

Article

Expression levels of thymidylate synthase may help point the way to new treatment options for patients with ALK-positive NSCLC, including combination therapy.